May 01, 2026 | FDA Approves First PROTAC Drug Veppanu; Pharma M&A Hits $84B in Q1; Truqap Clears ODAC 7-1

FDA clears Veppanu, the first protein degrader to reachmarket — but no commercial partner in sight. Q1 biopharma M&A hits $84B as patent cliff urgency drives a mega year. Plus: Truqap wins 7-1 ODAC vote in prostate cancer, Auvelity expands into Alzheimer's agitation, and Summit's ivonescimab stumbles before ASCO.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Veppanu,vepdegestrant, Arvinas, Pfizer, PROTAC, protein degrader, breast cancer, FDA approval, AstraZeneca, Truqap, capivasertib, ODAC, prostate cancer, SummitTherapeutics, ivonescimab, Esperion, ArchiMed, Teva, Emalex, ecopipam, Tourette syndrome, Axsome, Auvelity, Alzheimer's agitation, Moderna, Amgen, obesity,Tavneos, Chiesi, KalVista, Ligand, XOMA, Avalyn, Elrexfio, Lilly, Foundayo, Samsung Biologics, UniQure, Huntington's, pharma M&A, patent cliff, Merck, Gilead